AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advan
Go back to AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advan| AbbVie (NYSE: ABBV) | Delayed: 227.73 +2.96 (1.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $224.77 | 52 Week High | $68.12 | |||
| Open | $227.50 | 52 Week Low | $50.71 | |||
| Day High | $228.40 | P/E | 49.40 | |||
| Day Low | $224.32 | EPS | $4.61 | |||
| Volume | 4,086,391 | |||||
